This is a table of type trigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
trigram | frequency |
---|---|
as well as | 110 |
of the trial | 98 |
of clinical trials | 85 |
the use of | 81 |
in clinical trials | 77 |
the number of | 74 |
in patients with | 69 |
the treatment of | 67 |
trial and error | 65 |
the impact of | 62 |
in order to | 60 |
need to be | 59 |
of the pandemic | 52 |
of the study | 51 |
during the covid | 50 |
versus standard care | 50 |
to participate in | 48 |
based on the | 48 |
in the trial | 47 |
evidence of a | 47 |
severe acute respiratory | 47 |
there is a | 46 |
according to the | 46 |
serious adverse events | 45 |
efficacy and safety | 42 |
due to the | 42 |
as a result | 42 |
patients with covid | 41 |
in terms of | 40 |
clinical trials in | 40 |
randomized controlled trial | 40 |
and safety of | 39 |
acute respiratory syndrome | 39 |
respiratory distress syndrome | 38 |
the united states | 37 |
of patients with | 36 |
the risk of | 36 |
randomised controlled trials | 36 |
the majority of | 35 |
for the treatment | 35 |
the effect of | 34 |
the time of | 33 |
respiratory syndrome coronavirus | 33 |
data will be | 33 |
acute respiratory distress | 33 |
treatment of covid | 33 |
in the treatment | 32 |
world health organization | 32 |
randomized clinical trial | 32 |
one of the | 32 |
a number of | 32 |
in addition to | 31 |
the need for | 31 |
trial sequential analysis | 30 |
a systematic review | 30 |
randomised controlled trial | 30 |
such as the | 30 |
the role of | 30 |
in accordance with | 30 |
showed evidence of | 30 |
in the united | 29 |
of the trials | 29 |
participants will be | 28 |
in the first | 28 |
the first trial | 28 |
clinical trials during | 28 |
the results of | 28 |
during the pandemic | 28 |
there is no | 28 |
chronic obstructive pulmonary | 27 |
the possibility of | 27 |
obstructive pulmonary disease | 27 |
a total of | 27 |
of the covid | 27 |
there was no | 26 |
the conduct of | 26 |
the context of | 26 |
trial of phase | 26 |
be used to | 26 |
the end of | 26 |
impact of the | 26 |
may not be | 26 |
the effects of | 26 |
randomized clinical trials | 26 |
at the time | 25 |
in developing countries | 25 |
of clinical research | 25 |
the control group | 25 |
understanding of the | 25 |
the absence of | 25 |
risk of bias | 25 |
critically ill patients | 24 |
acute respiratory failure | 24 |
accordance with the | 24 |
randomized controlled trials | 24 |
no evidence of | 24 |
the basis of | 24 |
included in the | 24 |
food and drug | 24 |
for clinical trials | 24 |
the management of | 24 |
analysis of the | 24 |
clinical trials and | 24 |
the clinical trial | 23 |
the primary outcome | 23 |
a result of | 23 |
trial will be | 23 |
related to the | 23 |
quality of life | 23 |
standard of care | 23 |
first trial of | 23 |
and drug administration | 23 |
it may be | 23 |
the duration of | 22 |
clinical trials for | 22 |
that can be | 22 |
of the intervention | 22 |
to assess the | 22 |
beneficial effect of | 22 |
proportion of patients | 22 |
clinical trials of | 22 |
of clinical trial | 22 |
a lack of | 22 |
of a beneficial | 22 |
in the study | 22 |
a clinical trial | 21 |
phase iii trials | 21 |
the quality of | 21 |
very low certainty | 21 |
high risk of | 21 |
the development of | 21 |
nonserious adverse events | 21 |
twice daily for | 21 |
with acute respiratory | 21 |
a beneficial effect | 21 |
standard care on | 21 |
of a difference | 20 |
will be conducted | 20 |
the trial will | 20 |
days after randomization | 20 |
in the context | 20 |
on the basis | 20 |
may need to | 20 |
the live home | 19 |
with severe covid | 19 |
results of a | 19 |
end of the | 19 |
conduct of clinical | 19 |
because of the | 19 |
patients will be | 19 |
controlled trial of | 19 |
likely to be | 19 |
to evaluate the | 19 |
the importance of | 19 |
part of the | 19 |
remdesivir versus placebo | 19 |
in this study | 19 |
for patients with | 19 |
a randomized clinical | 19 |
be able to | 19 |
of the task | 19 |
for the trial | 18 |
during a pandemic | 18 |
will be used | 18 |
three age groups | 18 |
of hydroxychloroquine in | 18 |
some of the | 18 |
to ensure that | 18 |
will be performed | 18 |
of missing data | 18 |
standard care alone | 18 |
will need to | 18 |
the implementation of | 18 |
the trial is | 18 |
of the data | 18 |
a difference between | 18 |
living systematic review | 18 |
the efficacy of | 17 |
analysis showed no | 17 |
the copyright holder | 17 |
phase ii trials | 17 |
to standard care | 17 |
in the absence | 17 |
to the pandemic | 17 |
standard care versus | 17 |
the course of | 17 |
should be considered | 17 |
of safety data | 17 |
the process of | 17 |
may also be | 17 |
to be considered | 17 |
well as the | 17 |
will not be | 17 |
care versus standard | 17 |
added to standard | 17 |
the world health | 17 |
to display the | 17 |
most of the | 17 |
this article is | 17 |
of coronavirus disease | 17 |
acute lung injury | 17 |
patients with severe | 17 |
approved by the | 16 |
clinical trials are | 16 |
on serious adverse | 16 |
the safety of | 16 |
it is not | 16 |
relative risk reduction | 16 |
we found that | 16 |
systematic review of | 16 |
a trial of | 16 |
below the ball | 16 |
the need to | 16 |
needs to be | 16 |
in clinical research | 16 |
the trial and | 16 |
the proportion of | 16 |
the potential for | 16 |
showed no evidence | 16 |
we did not | 16 |
in critically ill | 16 |
systematic review and | 16 |
at least one | 16 |
children with acute | 16 |
with regard to | 16 |
as part of | 16 |
this is a | 16 |
total number of | 16 |
on clinical trials | 16 |
institutional review boards | 16 |
the research team | 16 |
depending on the | 16 |
of this article | 16 |
safety and efficacy | 16 |
good clinical practice | 16 |
trials in phase | 16 |
of this study | 16 |
the patient is | 15 |
in light of | 15 |
in response to | 15 |
there may be | 15 |
granted medrxiv a | 15 |
the total number | 15 |
hospitalized patients with | 15 |
a randomized controlled | 15 |
will be collected | 15 |
holder for this | 15 |
license to display | 15 |
willingness to participate | 15 |
in this trial | 15 |
the design of | 15 |
has granted medrxiv | 15 |
impact on the | 15 |
a license to | 15 |
it is important | 15 |
the preprint in | 15 |
trials in the | 15 |
in relation to | 15 |
copyright holder for | 15 |
due to covid | 15 |
display the preprint | 15 |
is important to | 15 |
preprint in perpetuity | 15 |
by the pandemic | 15 |
results from the | 15 |
a review of | 15 |
who has granted | 15 |
for this preprint | 15 |
medrxiv a license | 15 |
access to the | 14 |
can be found | 14 |
of chronic obstructive | 14 |
made available under | 14 |
from the trial | 14 |
the trial results | 14 |
in the same | 14 |
results of the | 14 |
is likely to | 14 |
the most efficient | 14 |
use of the | 14 |
members of the | 14 |
intermittent preventive treatment | 14 |
versus placebo on | 14 |
the analysis of | 14 |
east respiratory syndrome | 14 |
available under a | 14 |
is defined as | 14 |
around the world | 14 |
was associated with | 14 |
clinical trials that | 14 |
the start of | 14 |
required information size | 14 |
after randomization in | 14 |
the lack of | 14 |
it is made | 14 |
a range of | 14 |
in the case | 14 |
is made available | 14 |
of the vaccine | 14 |
with or without | 14 |
be carried out | 14 |
none of the | 14 |
international license it | 14 |
ongoing clinical trials | 14 |
middle east respiratory | 14 |
the authors declare | 14 |
associated with a | 14 |
license it is | 14 |
can be used | 14 |
treatment of patients | 14 |
no significant difference | 14 |
of the clinical | 14 |
will also be | 14 |
the miracle trial | 13 |
randomization in the | 13 |
number of trials | 13 |
the presence of | 13 |
the treatment effect | 13 |
the university of | 13 |
analysis showed that | 13 |
of a randomized | 13 |
a way that | 13 |
the effectiveness of | 13 |
not possible to | 13 |
it would be | 13 |
participants in the | 13 |
the ability to | 13 |
based on a | 13 |
european medicines agency | 13 |
will be reported | 13 |
the most common | 13 |
at the same | 13 |
prior to the | 13 |
the fact that | 13 |
traditional chinese medicine | 13 |
of trials in | 13 |
should not be | 13 |
of trial and | 13 |
of these trials | 13 |
the case of | 13 |
review and meta | 13 |
the scientific community | 13 |
the novel coronavirus | 13 |
a variety of | 13 |
of adverse events | 13 |
half of the | 13 |
malaria in pregnancy | 13 |
whether or not | 13 |
for treatment of | 13 |
with respect to | 13 |
masks and respirators | 13 |
in the us | 13 |
implementation of the | 13 |
clinical trial of | 13 |
treatments for covid | 13 |
of the disease | 12 |
version posted june | 12 |
analysis of safety | 12 |
morbidity and mortality | 12 |
of the primary | 12 |
at high risk | 12 |
this version posted | 12 |
in line with | 12 |
claims in published | 12 |
for the first | 12 |
the prevention of | 12 |
it is also | 12 |
a phase iii | 12 |
to the trial | 12 |
to clinical trials | 12 |
review of the | 12 |
as compared with | 12 |
and serious adverse | 12 |
in published maps | 12 |
number of days | 12 |
this preprint this | 12 |
trials during the | 12 |
each of the | 12 |
the author funder | 12 |
at the end | 12 |
one or more | 12 |
and treatment of | 12 |
published maps and | 12 |
the validity of | 12 |
to jurisdictional claims | 12 |
to do so | 12 |
large number of | 12 |
in the event | 12 |
was no significant | 12 |
on the trial | 12 |
regard to jurisdictional | 12 |
in a way | 12 |
ensure that the | 12 |
impact of covid | 12 |
adverse events in | 12 |
in which the | 12 |
maps and institutional | 12 |
there is an | 12 |
in phase i | 12 |
it has been | 12 |
and institutional affiliations | 12 |
in the control | 12 |
remains neutral with | 12 |
a combination of | 12 |
is based on | 12 |
is the author | 12 |
related to covid | 12 |
springer nature remains | 12 |
jurisdictional claims in | 12 |
neutral with regard | 12 |
type i error | 12 |
nature remains neutral | 12 |
preprint this version | 12 |
was used to | 12 |
use of it | 12 |
focus on the | 12 |
the cumulative z | 12 |
that it is | 12 |
the pangolin could | 12 |
will be provided | 11 |
intensive care unit | 11 |
to make a | 11 |
it was not | 11 |
many of the | 11 |
that they have | 11 |
risk of infection | 11 |
of the drug | 11 |
source data verification | 11 |
it will be | 11 |
daily for days | 11 |
and exclusion criteria | 11 |
patients with acute | 11 |
the full protocol | 11 |
to minimize the | 11 |
start of the | 11 |
used the same | 11 |
d proportion of | 11 |
and measures to | 11 |
trials of surfactant | 11 |
for the primary | 11 |
data and safety | 11 |
participate in the | 11 |
a is the | 11 |
participate in clinical | 11 |
note springer nature | 11 |
more likely to | 11 |
characteristics of the | 11 |
trials in which | 11 |
data from the | 11 |
in the design | 11 |
of the evidence | 11 |
during the trial | 11 |
for healthcare workers | 11 |
suggests that the | 11 |
as soon as | 11 |
their first trial | 11 |
no competing interests | 11 |
in treatment of | 11 |
people with dementia | 11 |
showed that we | 11 |
number of participants | 11 |
respiratory syncytial virus | 11 |
of a trial | 11 |
be used for | 11 |
has been shown | 11 |
public health emergency | 11 |
the outcome of | 11 |
of mechanical ventilation | 11 |
statement of intent | 11 |
under a is | 11 |
protocol for a | 11 |
will be recorded | 11 |
the statistical analysis | 11 |
individual patient data | 11 |
hospitalized with severe | 11 |
that there is | 11 |
in a trial | 11 |
the same time | 11 |
may lead to | 11 |
the experimental group | 11 |
there are no | 11 |
in children with | 11 |
patients admitted to | 10 |
clinical research in | 10 |
could also be | 10 |
plot and measures | 10 |
the efficacy and | 10 |
to be more | 10 |
this paper at | 10 |
adults hospitalized with | 10 |
measures to quantify | 10 |
if there is | 10 |
authors declare that | 10 |
during this pandemic | 10 |
to confirm or | 10 |
during the study | 10 |
the timing of | 10 |
international conference on | 10 |
to quantify heterogeneity | 10 |
clinical trials registry | 10 |
they have no | 10 |
use of a | 10 |
be considered as | 10 |
the forest plot | 10 |
which may be | 10 |
of masks and | 10 |
used in the | 10 |
the purpose of | 10 |
declare that they | 10 |
validity of the | 10 |
international clinical trials | 10 |
analysis of trials | 10 |
inclusion and exclusion | 10 |
and efficacy of | 10 |
the informed consent | 10 |
in the face | 10 |
for those who | 10 |
a relative risk | 10 |
the patient will | 10 |
response to the | 10 |
to ensure the | 10 |
by the covid | 10 |
in pharmaceutical companies | 10 |
enough information to | 10 |
information about the | 10 |
of the forest | 10 |
to the study | 10 |
in the future | 10 |
of novel coronavirus | 10 |
during the current | 10 |
clinical characteristics of | 10 |
the developing world | 10 |
participated in the | 10 |
and reporting of | 10 |
the task and | 10 |
data monitoring committee | 10 |
there was a | 10 |
analyses will be | 10 |
inspection of the | 10 |
and in the | 10 |
in hospitalized patients | 10 |
clinical trials on | 10 |
and will be | 10 |
systematic reviews and | 10 |
in the field | 10 |
the face of | 10 |
be found in | 10 |
hydroxychloroquine versus standard | 10 |
will be compared | 10 |
of patients and | 10 |
the pandemic and | 10 |
in a clinical | 10 |
the case for | 10 |
the trial was | 10 |
time to clinical | 10 |
the spread of | 10 |
institutes of health | 10 |
straws below the | 10 |
data collection and | 10 |
for the prevention | 10 |
of surfactant in | 10 |
forest plot and | 10 |
head and neck | 10 |
the introduction of | 10 |
in the analysis | 10 |
to address the | 10 |
days will be | 10 |
paper at https | 10 |
the study will | 10 |
this study is | 10 |
hydroxychloroquine in patients | 10 |
if it is | 10 |
patients with dementia | 10 |
visual inspection of | 10 |
data should be | 10 |
consent to participate | 10 |
many of these | 9 |
on how to | 9 |
we argue that | 9 |
or in the | 9 |
trials should be | 9 |
evaluation of the | 9 |
of trials of | 9 |
and there is | 9 |
of a vaccine | 9 |
effects of the | 9 |
of the live | 9 |
participation in the | 9 |
more than one | 9 |
patients in the | 9 |
in the covid | 9 |
are likely to | 9 |
we focus on | 9 |
significant difference in | 9 |
of medical products | 9 |
sample size of | 9 |
number of patients | 9 |
the second trial | 9 |
were included in | 9 |
in collaboration with | 9 |
to the patient | 9 |
that do not | 9 |
data on the | 9 |
mg kg twice | 9 |
statistical analysis of | 9 |
of picu stay | 9 |
duration of picu | 9 |
the clinical trials | 9 |
time of writing | 9 |
and their caregivers | 9 |
of the research | 9 |
study protocol for | 9 |
included in this | 9 |
moderate to severe | 9 |
changes in the | 9 |
in this case | 9 |
difference in the | 9 |
sequential analysis showed | 9 |
with the task | 9 |
the younger children | 9 |
the three age | 9 |
is that the | 9 |
schmitz et al | 9 |
conducting clinical trials | 9 |
kg twice daily | 9 |
is the first | 9 |
with the same | 9 |
will be presented | 9 |
the aim of | 9 |
cancer clinical trials | 9 |
acute exacerbation of | 9 |
confirm or reject | 9 |
safety monitoring board | 9 |
the it artefact | 9 |
risk reduction of | 9 |
with a relative | 9 |
collaboration with the | 9 |
in a pandemic | 9 |
involved in the | 9 |
study of the | 9 |
course of the | 9 |
the current pandemic | 9 |
this is the | 9 |
the pandemic on | 9 |
of undue influence | 9 |
the sample size | 9 |
the intervention period | 9 |
analysis showed evidence | 9 |
influenced by the | 9 |
a randomized trial | 9 |
us food and | 9 |
on the management | 9 |
national institutes of | 9 |
with the aim | 9 |
trials registry platform | 9 |
central statistical monitoring | 9 |
case report form | 9 |
that may be | 9 |
use of masks | 9 |
the protection of | 9 |
will be assessed | 9 |
any of the | 9 |
patients with the | 9 |
did not cross | 9 |
patients treated with | 9 |
the steering committee | 9 |
treatment for covid | 9 |
policy trial emulation | 9 |
and safety monitoring | 9 |
of health and | 9 |
to clinical improvement | 9 |
in the clinical | 9 |
is not possible | 9 |
to use the | 9 |
this statement of | 9 |
of the treatment | 9 |
the choice of | 9 |
serious adverse event | 9 |
due to a | 9 |
statistical analysis plan | 9 |
and trial sequential | 9 |
the ball and | 9 |
by the number | 9 |
in adults hospitalized | 9 |
who cannot take | 9 |
could not be | 9 |
of participants in | 9 |
distrust in pharmaceutical | 9 |
trials of medical | 9 |
associated with the | 9 |
in adults with | 9 |
not cross the | 9 |
nature of the | 9 |
in the second | 9 |
to have a | 9 |
the field of | 9 |
trials can be | 9 |
are able to | 9 |
of informed consent | 9 |
health care workers | 9 |
a hypothetical strategy | 9 |
the severe acute | 9 |
the success of | 9 |
the characteristics of | 9 |
during the first | 9 |
role in the | 9 |
to the intervention | 9 |
may be considered | 9 |
is expected to | 9 |
will have to | 9 |
to meet the | 9 |
of bubonic plague | 8 |
days of the | 8 |
the trial design | 8 |
be required to | 8 |
written informed consent | 8 |
of lopinavir ritonavir | 8 |
the pandemic in | 8 |
proportion of trials | 8 |
to receive the | 8 |
the ards network | 8 |
to support the | 8 |
serious adverse reactions | 8 |
lopinavir ritonavir and | 8 |
of randomised controlled | 8 |
the location of | 8 |
guidance on the | 8 |
of public health | 8 |
light of the | 8 |
was not possible | 8 |
as at high | 8 |
it should be | 8 |
assessed as at | 8 |
for each trial | 8 |
the pharmaceutical industry | 8 |
results from a | 8 |
so as to | 8 |
duration of ventilation | 8 |
experience with the | 8 |
repurposed for covid | 8 |
will be the | 8 |
of the safety | 8 |
a minimum of | 8 |
medical products during | 8 |
possible to perform | 8 |
the event of | 8 |
patients with moderate | 8 |
the trials were | 8 |
be given to | 8 |
will be made | 8 |
effect of hydroxychloroquine | 8 |
a set of | 8 |
trial randomizing participants | 8 |
with the tablet | 8 |
treatment of malaria | 8 |
the us food | 8 |
action sequence in | 8 |
the study is | 8 |
trial of lopinavir | 8 |
clinical research and | 8 |
there has been | 8 |
the case report | 8 |
analysis will be | 8 |
of severe acute | 8 |
the data protection | 8 |
in critical care | 8 |
the identification of | 8 |
the aim to | 8 |
care on serious | 8 |
throughout the trial | 8 |
the included trials | 8 |
some of these | 8 |
trials may be | 8 |
will be randomized | 8 |
by the research | 8 |
as source control | 8 |
for mechanical ventilation | 8 |
outcomes will be | 8 |
an opportunity to | 8 |
the european medicines | 8 |
where the user | 8 |
of vaccine protection | 8 |
member of the | 8 |
will be assigned | 8 |
the value of | 8 |
and public health | 8 |
increased risk of | 8 |
information accompanies this | 8 |
responsible for the | 8 |
the second stage | 8 |
and missing data | 8 |
data protection regulation | 8 |
a serious adverse | 8 |
in clinical trial | 8 |
on the ipad | 8 |
the opportunity to | 8 |
when they are | 8 |
trial steering committee | 8 |
has not been | 8 |
affected by the | 8 |
and may be | 8 |
is not a | 8 |
to identify the | 8 |
the primary analysis | 8 |
to the research | 8 |
on nonserious adverse | 8 |
at any time | 8 |
be associated with | 8 |
supplementary information accompanies | 8 |
has been used | 8 |
of vaccine candidates | 8 |
most of these | 8 |
accompanies this paper | 8 |
are based on | 8 |
we used the | 8 |
surfactant in children | 8 |
approval of the | 8 |
sponsors and investigators | 8 |
in spite of | 8 |
institutional review board | 8 |
weighted mean difference | 8 |
across the three | 8 |
high level of | 8 |
products during covid | 8 |
management of clinical | 8 |
so that the | 8 |
trial is to | 8 |
addition to the | 8 |
d and d | 8 |
those who cannot | 8 |
not included in | 8 |
the principle of | 8 |
clinical trial sponsors | 8 |
clinical trial designs | 8 |
this may be | 8 |
out of the | 8 |
in the experimental | 8 |
within days will | 8 |
on adverse events | 8 |
prevention and treatment | 8 |
proportion of participants | 8 |
need to take | 8 |
the name of | 8 |
in additional file | 8 |
should be given | 8 |
in this paper | 8 |
all three age | 8 |
approval from the | 8 |
and interpretation of | 8 |
society and conservation | 8 |
intravenous vitamin c | 8 |
the primary endpoint | 8 |
trials have been | 8 |
a randomised controlled | 8 |
between the two | 8 |
the availability of | 8 |
from the patient | 8 |
related missing data | 8 |
novel coronavirus pneumonia | 8 |
efficacy of a | 8 |
of patients who | 8 |
given that the | 8 |
development of the | 8 |
the data will | 8 |
from the study | 8 |
in the community | 8 |
reviews and meta | 8 |
personal protective equipment | 8 |
in a timely | 8 |
the trial sequential | 8 |
to use a | 8 |
of the most | 8 |
in health care | 8 |
n a l | 7 |
in both the | 7 |
make a choice | 7 |
the benefit of | 7 |
were assessed as | 7 |
surfactant was associated | 7 |
there are many | 7 |
university of oxford | 7 |
renal replacement therapy | 7 |
and observational studies | 7 |
uncorrected axillary temperature | 7 |
of hydroxychloroquine on | 7 |
adjusted required information | 7 |
are included in | 7 |
caused by the | 7 |
in contrast to | 7 |
that cannot be | 7 |
of dead ants | 7 |
o u r | 7 |
of randomized controlled | 7 |
the belmont report | 7 |
trial should be | 7 |
a high level | 7 |
the two groups | 7 |
as long as | 7 |
in phase ii | 7 |
ill patients with | 7 |
that the pangolin | 7 |
for the pwd | 7 |
cause mortality and | 7 |
is that of | 7 |
clinical trials to | 7 |
the it device | 7 |
adverse events with | 7 |
most efficient method | 7 |
and days after | 7 |
to health care | 7 |
wolters kluwer health | 7 |
of trial results | 7 |
withdraw from the | 7 |
this can be | 7 |
of the efficacy | 7 |
trials that were | 7 |
as defined by | 7 |
and institutional review | 7 |
recruitment and retention | 7 |
informed consent to | 7 |
in recent years | 7 |
of the present | 7 |
of data collection | 7 |
preventive treatment of | 7 |
will take place | 7 |
die within days | 7 |
results will be | 7 |
ebola virus disease | 7 |
adverse events and | 7 |
the placebo group | 7 |
is a major | 7 |
in the time | 7 |
provided with standard | 7 |
in each group | 7 |
trial sequential monitoring | 7 |
days number of | 7 |
versus medical management | 7 |
p r o | 7 |
may be needed | 7 |
primary outcome measure | 7 |
of the total | 7 |
that they are | 7 |
to provide a | 7 |
to be the | 7 |
which is a | 7 |
in the live | 7 |
clinical trial research | 7 |
followed by ciprofloxacin | 7 |
guidance for industry | 7 |
to describe the | 7 |
that are not | 7 |
on the registry | 7 |
care on all | 7 |
summary of the | 7 |
on conduct of | 7 |
trial has been | 7 |
is associated with | 7 |
be treated with | 7 |
the main trial | 7 |
context of the | 7 |
in randomised controlled | 7 |
unauthorized reproduction of | 7 |
will be sent | 7 |
and type ii | 7 |
to reduce the | 7 |
with a deviated | 7 |
duration of mechanical | 7 |
the safety and | 7 |
on behalf of | 7 |
efficacy of hydroxychloroquine | 7 |
p r e | 7 |
of the statistical | 7 |
missing data in | 7 |
the certainty of | 7 |
trials in developing | 7 |
trials that are | 7 |
we believe that | 7 |
and the impact | 7 |
the clinical study | 7 |
regardless of whether | 7 |
this study was | 7 |
can be ethically | 7 |
in the eu | 7 |
sample size and | 7 |
effect of dexamethasone | 7 |
surgical clinical trials | 7 |
in a similar | 7 |
for systematic reviews | 7 |
of human subjects | 7 |
to investigate the | 7 |
was a significant | 7 |
the status of | 7 |
assigned the value | 7 |
at the university | 7 |
to determine the | 7 |
of the sites | 7 |
same action sequence | 7 |
l p r | 7 |
phase i trials | 7 |
and error behaviour | 7 |
trial design and | 7 |
of registered trials | 7 |
the study and | 7 |
to increase the | 7 |
supported by the | 7 |
carried out in | 7 |
the first days | 7 |
for clinical research | 7 |
using the tablet | 7 |
assessment of the | 7 |
tumor necrosis factor | 7 |
urgent need for | 7 |
a l p | 7 |
interaction with the | 7 |
of in the | 7 |
and that the | 7 |
phase iii trial | 7 |
that of the | 7 |
certainty of the | 7 |
before and after | 7 |
of the nasal | 7 |
the patient and | 7 |
a measure of | 7 |
to take part | 7 |
treatment of severe | 7 |
such as those | 7 |
would need to | 7 |
declaration of helsinki | 7 |
the beginning of | 7 |
in more than | 7 |
explanation and elaboration | 7 |
it is the | 7 |
the time to | 7 |
potential treatments for | 7 |
patients and the | 7 |
and the data | 7 |
is especially important | 7 |
j o u | 7 |
patients who die | 7 |
of negative disconfirmation | 7 |
author impact score | 7 |
be conducted in | 7 |
r n a | 7 |
with azithromycin and | 7 |
were able to | 7 |
trials are needed | 7 |
on the use | 7 |
a deviated septum | 7 |
the amount of | 7 |
differences in the | 7 |
in the medical | 7 |
based on their | 7 |
version of the | 7 |
to complete the | 7 |
to define the | 7 |
result of the | 7 |
may have been | 7 |
research ethics committee | 7 |
primary and secondary | 7 |
research and development | 7 |
used an efficient | 7 |
the rest of | 7 |
will be available | 7 |
the current covid | 7 |
for participation in | 7 |
can lead to | 7 |
trial and days | 7 |
in the presence | 7 |
a living mapping | 7 |
of malaria in | 7 |
exacerbation of copd | 7 |
the decision to | 7 |
first trial and | 7 |
be used in | 7 |
days after enrollment | 7 |
reproduction of this | 7 |
duration of the | 7 |
these trials are | 7 |
of remdesivir versus | 7 |
clinical trials have | 7 |
of life in | 7 |
for the study | 7 |
the benefits of | 7 |
they can be | 7 |
in the previous | 7 |
development of a | 7 |
treatment effects in | 7 |
ritonavir in adults | 7 |
guidance on conduct | 7 |
of the new | 7 |
in the s | 7 |
who die within | 7 |
the evidence was | 7 |
clinical trials is | 7 |
the implementation process | 7 |
compared to the | 7 |
the potential to | 7 |
a framework for | 7 |
have no competing | 7 |
study is to | 7 |
missing data and | 7 |
of the patients | 7 |
used as a | 7 |
free days number | 7 |
u r n | 7 |
hospitalised patients with | 7 |
number of covid | 7 |
it is possible | 7 |
based quality management | 7 |
the definition of | 7 |
r o o | 7 |
be assigned the | 7 |
the recovery trial | 7 |
safety data in | 7 |
are needed to | 7 |
in the protocol | 7 |
sequential monitoring boundaries | 7 |
the reviewed trials | 7 |
patients who have | 7 |
a series of | 7 |
o o f | 7 |
in these trials | 7 |
article is prohibited | 7 |
can only be | 7 |
to determine whether | 7 |
clinical trial data | 7 |
research in the | 7 |
to be used | 7 |
the pangolins were | 7 |
clinical trial results | 7 |
pwds and their | 7 |
group will be | 7 |
the required information | 6 |
to the extent | 6 |
the assessment of | 6 |
and error is | 6 |
when there is | 6 |
of the effect | 6 |
at the site | 6 |
when the trial | 6 |
trial emulation framework | 6 |
the kcdc guideline | 6 |
the acute respiratory | 6 |
indicated no heterogeneity | 6 |
red outward sloping | 6 |
x x x | 6 |
shortness of breath | 6 |
trials for covid | 6 |
to allow for | 6 |
led clinical trials | 6 |
in our study | 6 |
characterized by a | 6 |
of the epidemic | 6 |
iv twice daily | 6 |
of treatment effect | 6 |
are required to | 6 |
the clinical research | 6 |
prophylaxis with azithromycin | 6 |
patient safety and | 6 |
as an additional | 6 |
results of an | 6 |
of the main | 6 |
similar to the | 6 |
on the conduct | 6 |
how do we | 6 |
should be taken | 6 |
trials related to | 6 |
conducted in accordance | 6 |
in hospitalised patients | 6 |
lung injury and | 6 |
article is protected | 6 |
line shows conventional | 6 |
risk of death | 6 |
where there is | 6 |
for safety data | 6 |
within the first | 6 |
not have enough | 6 |
proactive prophylaxis with | 6 |
type of trial | 6 |
on or before | 6 |
of this approach | 6 |
use of hydroxychloroquine | 6 |
the safety profile | 6 |
of patients experiencing | 6 |
mechanical ventilation in | 6 |
the most important | 6 |
be the case | 6 |
the performance of | 6 |
used to assess | 6 |
quality clinical trials | 6 |
this will be | 6 |
adverse events not | 6 |
be interpreted with | 6 |
benefit or harm | 6 |
to contribute to | 6 |
with standard supportive | 6 |
patients experiencing a | 6 |
was based on | 6 |
the k th | 6 |
trials on covid | 6 |
exacerbations of chronic | 6 |
made efficient responses | 6 |
can be considered | 6 |
have access to | 6 |
risk ratio reduction | 6 |
small sample size | 6 |
for the duration | 6 |
trial a randomized | 6 |
care and research | 6 |
trial design for | 6 |
the coronavirus pandemic | 6 |
should be interpreted | 6 |
the trial has | 6 |
consent to research | 6 |
in using the | 6 |
disease in china | 6 |
and the need | 6 |
the treating physician | 6 |
in the academic | 6 |
to the protocol | 6 |
daily for those | 6 |
whether the patient | 6 |
action sequences in | 6 |
can also be | 6 |
of the impact | 6 |
analysis and reporting | 6 |
due to pandemic | 6 |
data management and | 6 |
of respiratory failure | 6 |
of the following | 6 |
preferred reporting items | 6 |
there is also | 6 |
that were efficient | 6 |
are eligible for | 6 |
patients with a | 6 |
registered in the | 6 |
the likelihood of | 6 |
reject that hydroxychloroquine | 6 |
daris was calculated | 6 |
be performed on | 6 |
stages of the | 6 |
of participants and | 6 |
to account for | 6 |
is a clear | 6 |
immortal time bias | 6 |
described in the | 6 |
a harmful effect | 6 |
this pandemic has | 6 |
the evolution of | 6 |
participation in clinical | 6 |
whether it is | 6 |
calculated based on | 6 |
trial of the | 6 |
in this review | 6 |
a spectrum of | 6 |
which was not | 6 |
we performed a | 6 |
the primary objective | 6 |
contribute to the | 6 |
of copd exacerbation | 6 |
ritonavir and interferon | 6 |
sloping red lines | 6 |
trials randomizing patients | 6 |
use is not | 6 |
the coordinator will | 6 |
in control group | 6 |
we do not | 6 |
in the primary | 6 |
and of the | 6 |
of the children | 6 |
controlled trials in | 6 |
early phase clinical | 6 |
one single trial | 6 |
to the patients | 6 |
that there was | 6 |
group randomised trials | 6 |
as shown in | 6 |
dose of mg | 6 |
effect of remdesivir | 6 |
between care and | 6 |
the live intervention | 6 |
an array of | 6 |
in dementia care | 6 |
it is of | 6 |
the containers were | 6 |
phase iib trials | 6 |
cannot take oral | 6 |
of remdesivir for | 6 |
immune responses in | 6 |
as one of | 6 |
chimpanzees and gorillas | 6 |
who international clinical | 6 |
within days of | 6 |
we expect the | 6 |
that the tablet | 6 |
the data and | 6 |
the coronavirus disease | 6 |
monitoring boundaries for | 6 |
the completion of | 6 |
the results were | 6 |
the nature of | 6 |
referred to as | 6 |
reporting items for | 6 |
for the use | 6 |
effect of the | 6 |
protected by copyright | 6 |
all of the | 6 |
the incidence of | 6 |
used for the | 6 |
or before d | 6 |
before d proportion | 6 |
during the intervention | 6 |
placebo on serious | 6 |
was calculated based | 6 |
the magnitude of | 6 |
experiencing a serious | 6 |
on day and | 6 |
is a key | 6 |
a dose of | 6 |
it is imperative | 6 |
of a phase | 6 |
will be analyzed | 6 |
clinical trial registry | 6 |
in cancer patients | 6 |
for human use | 6 |
to improve the | 6 |
social network analysis | 6 |
factors associated with | 6 |
is characterized by | 6 |
period of time | 6 |
safety data analysis | 6 |
in a single | 6 |
phase clinical trials | 6 |
for cancer patients | 6 |
in this context | 6 |
face mask use | 6 |
all data will | 6 |
green dotted line | 6 |
trial with a | 6 |
exclude the possibility | 6 |
to find the | 6 |
the trial in | 6 |
of trials that | 6 |
no role in | 6 |
the nairos trial | 6 |
this trial is | 6 |
conference on harmonisation | 6 |
ratio reduction of | 6 |
respiratory failure in | 6 |
will be asked | 6 |
a proportion of | 6 |
the participants will | 6 |
at this time | 6 |
boundaries for benefit | 6 |
in this setting | 6 |
of the population | 6 |
sample size is | 6 |
number of confirmed | 6 |
of trial participants | 6 |
the impact on | 6 |
across the world | 6 |
the standard of | 6 |
dexamethasone versus standard | 6 |
the daris was | 6 |
the who international | 6 |
the type of | 6 |
were not included | 6 |
and the first | 6 |
i error of | 6 |
first days after | 6 |
such as a | 6 |
in doing so | 6 |
pneumonia in wuhan | 6 |
will be evaluated | 6 |
to investigate whether | 6 |
have not been | 6 |
controlled clinical trial | 6 |
intention to treat | 6 |
the eligible trials | 6 |
to review the | 6 |
information is available | 6 |
participants in control | 6 |
ritonavir versus standard | 6 |
has been a | 6 |
is in the | 6 |
guidelines for reporting | 6 |
by the caregiver | 6 |
at all times | 6 |
in clinical studies | 6 |
the green dotted | 6 |
to focus on | 6 |
would like to | 6 |
parallel group randomised | 6 |
a summary of | 6 |
to be able | 6 |
evidence base for | 6 |
guidelines for the | 6 |
of this paper | 6 |
number of straws | 6 |
trial sequential analyses | 6 |
for which the | 6 |
events not considered | 6 |
presented with the | 6 |
extent to which | 6 |
information size was | 6 |
adhere to the | 6 |
clinical trials should | 6 |
of the patient | 6 |
of days within | 6 |
in clinical practice | 6 |
the patients in | 6 |
remdesivir for the | 6 |
mild to moderate | 6 |
take place in | 6 |
bagayogo et al | 6 |
is protected by | 6 |
the difference between | 6 |
dotted line shows | 6 |
for research participation | 6 |
distinction between care | 6 |
a call for | 6 |
and to the | 6 |
if a patient | 6 |
in this article | 6 |
not be able | 6 |
safety of the | 6 |
invasive mechanical ventilation | 6 |
at the national | 6 |
type ii error | 6 |
shows conventional boundaries | 6 |
the planning of | 6 |
analyses should be | 6 |
contributed to the | 6 |
combination of lopinavir | 6 |
being repurposed for | 6 |
general data protection | 6 |
aim of this | 6 |
the evidence base | 6 |
chemoprevention in pregnancy | 6 |
interventions for treatment | 6 |
different types of | 6 |
placebo on all | 6 |
electronic medical records | 6 |
the same action | 6 |
sequential analysis on | 6 |
of a study | 6 |
is an urgent | 6 |
patient data meta | 6 |
all rights reserved | 6 |
clinical trials the | 6 |
difference between the | 6 |
the trial emulation | 6 |
the efficiency of | 6 |
the principal investigator | 6 |
metastatic colorectal cancer | 6 |
clinical trials using | 6 |
can be achieved | 6 |
infection in the | 6 |
between d and | 6 |
the dexamethasone group | 6 |
that could be | 6 |
of relevant data | 6 |
but it is | 6 |
items for systematic | 6 |
of medical sciences | 6 |
trials were assessed | 6 |
in many ways | 6 |
lead to a | 6 |
cross the trial | 6 |
statistical methods for | 6 |
in the public | 6 |
expected to be | 6 |
the trial sponsor | 6 |
for reporting parallel | 6 |
this is not | 6 |
is funded by | 6 |
been shown to | 6 |
on the other | 6 |
a member of | 6 |
the trial protocol | 6 |
trials alongside genv | 6 |
persons with dementia | 6 |
conduct of the | 6 |
of the nose | 6 |
an impact on | 6 |
is shown in | 6 |
of the it | 6 |
clinical trial design | 6 |
to be a | 6 |
day and day | 6 |
to each other | 6 |
ii error of | 6 |
and conservation of | 6 |
is required for | 6 |
in the literature | 6 |
principles for clinical | 6 |
for adverse events | 6 |
standard supportive care | 6 |
in other countries | 6 |
reduction of in | 6 |
of the technology | 6 |
retrospective cohort study | 6 |
do not receive | 6 |
the benefits and | 6 |
should be conducted | 6 |
they will be | 6 |
control group of | 6 |
of the virus | 6 |
an urgent need | 6 |
a reduction in | 6 |
goal is to | 6 |
reporting parallel group | 6 |
event on or | 6 |
when they were | 6 |
with a median | 6 |
by the trial | 6 |
for benefit or | 6 |
with missing data | 6 |
the approval of | 6 |
days within the | 6 |
of phase i | 6 |
protection of human | 6 |
the trial statistician | 6 |
the two containers | 6 |
trials were registered | 6 |
in the standard | 6 |
clinical trial is | 6 |
comply with the | 6 |
adverse event on | 6 |
did not have | 6 |
with dementia and | 6 |
has been reported | 6 |
may be more | 6 |
emerging infectious diseases | 6 |
the publication of | 6 |
be reported as | 6 |
the target infection | 6 |
collection and analysis | 6 |
in the developing | 6 |
a case study | 6 |
in the uk | 6 |
the survey was | 6 |
with a combination | 6 |
be obtained from | 6 |
updated guidelines for | 6 |
the intensive care | 6 |
primary outcome of | 6 |
for the purpose | 6 |
in studies of | 6 |
is required to | 6 |
living mapping of | 6 |
randomisation will be | 6 |
number of authors | 6 |
therapies in the | 6 |
adaptive clinical trials | 6 |
a large number | 6 |
that the trial | 6 |
based on an | 6 |
patients who are | 6 |
the extent to | 6 |
the relationship between | 6 |
and did not | 6 |
common terminology criteria | 5 |
details of the | 5 |
intensive care units | 5 |
analyses and trial | 5 |
focused on the | 5 |
design of the | 5 |
take into account | 5 |
primary completion date | 5 |
and healthcare products | 5 |
effect of age | 5 |
measured by the | 5 |
are used to | 5 |
trials in korea | 5 |
on the same | 5 |
of the global | 5 |
they may be | 5 |
data may be | 5 |
false discovery rate | 5 |
primary outcome is | 5 |
a living systematic | 5 |
risk factors for | 5 |
enrollment when patients | 5 |
in bubo size | 5 |
due to high | 5 |
for the development | 5 |
this is an | 5 |
target trial emulation | 5 |
may be less | 5 |
the corresponding author | 5 |
objective of the | 5 |
cluster randomised trial | 5 |
of trials for | 5 |
be followed up | 5 |
severe plaque psoriasis | 5 |
orally twice daily | 5 |
south and southeast | 5 |
wedge futility line | 5 |
clinical trial participants | 5 |
defined as the | 5 |
be provided with | 5 |
be transferred to | 5 |
medical research council | 5 |
mortality and serious | 5 |
available from the | 5 |
the future of | 5 |
before the peak | 5 |
the length of | 5 |
approved the final | 5 |
of the tablet | 5 |
the change in | 5 |
shown to be | 5 |
and error may | 5 |
divided by the | 5 |
participation in a | 5 |
workshop on trade | 5 |
patients do not | 5 |
have enough information | 5 |
of it devices | 5 |
can be made | 5 |
the study treatment | 5 |
of a new | 5 |
information to confirm | 5 |
is available to | 5 |
of this manuscript | 5 |
the interest in | 5 |
should be documented | 5 |
of confirmed probable | 5 |
may be particularly | 5 |
creative commons licence | 5 |
the assessment time | 5 |
have been the | 5 |
clinical trial reporting | 5 |
lack of relevant | 5 |
as in the | 5 |
be difficult to | 5 |
clinical trials research | 5 |
in the last | 5 |
beaudry and pinsonneault | 5 |
these types of | 5 |
the sunda pangolin | 5 |
in the early | 5 |
in patients treated | 5 |
the academic literature | 5 |
randomised clinical trial | 5 |
the scope of | 5 |
systemic lupus erythematosus | 5 |
and clinical trials | 5 |
hand hygiene alone | 5 |
for malaria prevention | 5 |
a multicomponent intervention | 5 |
ferneley and sobreperez | 5 |
compared with the | 5 |
with severe acute | 5 |
reporting of the | 5 |
for the final | 5 |
be important to | 5 |
has shown that | 5 |
the setting of | 5 |
we note that | 5 |
dementia and their | 5 |
in the population | 5 |
not want to | 5 |
was to remove | 5 |
the usefulness of | 5 |
the same task | 5 |
outcome of the | 5 |
the cost of | 5 |
recruitment bias in | 5 |
randomised clinical trials | 5 |
trials may also | 5 |
is difficult to | 5 |
outcome was assessed | 5 |
involving human subjects | 5 |
of efficacy or | 5 |
for people with | 5 |
to achieve the | 5 |
with a high | 5 |
of a single | 5 |
is necessary to | 5 |
and clinical research | 5 |
of a pandemic | 5 |
an efficient solution | 5 |
the first two | 5 |
for human research | 5 |
products regulatory agency | 5 |
the outcome was | 5 |
the international conference | 5 |
study will be | 5 |
trial completion latency | 5 |
only two straws | 5 |
compassionate use of | 5 |
for the protection | 5 |
standard protocol items | 5 |
there are several | 5 |
as discussed above | 5 |
the responsibility of | 5 |
admitted to hospital | 5 |
a pandemic is | 5 |
have led to | 5 |
of rcts in | 5 |
be used as | 5 |
initial negative disconfirmation | 5 |
trade and conservation | 5 |
be randomized to | 5 |
the integrity of | 5 |
pangolins native to | 5 |
are essential to | 5 |
the administration of | 5 |
trials did not | 5 |
may be a | 5 |
in the intervention | 5 |
be delivered by | 5 |
main limitation of | 5 |
also need to | 5 |
will be measured | 5 |
data safety monitoring | 5 |
over half of | 5 |
revealed that there | 5 |
results on clinicaltrials | 5 |
of thousands of | 5 |
rather than a | 5 |
ii trials may | 5 |
adaptive structuration theory | 5 |
scientific community to | 5 |
institutional affiliations we | 5 |
with their first | 5 |
of days of | 5 |
of age on | 5 |
following negative disconfirmation | 5 |
allocated to the | 5 |
would not be | 5 |
admitted to the | 5 |
during a shift | 5 |
implications of the | 5 |
at d proportion | 5 |
native to south | 5 |
dexamethasone and remdesivir | 5 |
and quality of | 5 |
clinical trials conducted | 5 |
loss to follow | 5 |
united states food | 5 |
risks of systematic | 5 |
the ethics committee | 5 |
clinical study nurse | 5 |
the testing chamber | 5 |
evidence from the | 5 |
in their first | 5 |
standard care group | 5 |
will be obtained | 5 |
the generalizability of | 5 |
after the first | 5 |
depend on the | 5 |
in the pooled | 5 |
ii trials are | 5 |
continue to be | 5 |
assessed days after | 5 |
in healthcare workers | 5 |
and analysis of | 5 |
the frequency of | 5 |
patients with cancer | 5 |
retrieve the ball | 5 |
profile of the | 5 |
conflicts of interest | 5 |
appear to be | 5 |
is the total | 5 |
the standard care | 5 |
will be informed | 5 |
criteria for adverse | 5 |
contexts of use | 5 |
that aim to | 5 |
should be kept | 5 |
health care systems | 5 |
informed consent form | 5 |
trials and observational | 5 |
distrust in the | 5 |
of the severe | 5 |
placed on the | 5 |
with regards to | 5 |
as in phase | 5 |
the reasons for | 5 |
as a treatment | 5 |
statistical monitoring of | 5 |
than one trial | 5 |
as a potential | 5 |
or not the | 5 |
treatment of the | 5 |
be of interest | 5 |
treatment policy strategy | 5 |
and it is | 5 |
trials in a | 5 |
the help of | 5 |
live oral cholera | 5 |
of hydroxychloroquine for | 5 |
that we did | 5 |
eligible for inclusion | 5 |
of the device | 5 |
and chloroquine in | 5 |
this study are | 5 |
associated with more | 5 |
we identified trials | 5 |
efficient action sequence | 5 |
reduced the risk | 5 |
management of the | 5 |
the united kingdom | 5 |
such as sars | 5 |
natural history of | 5 |
by using the | 5 |
sent to the | 5 |
study of hydroxychloroquine | 5 |
participating in the | 5 |
be applied to | 5 |
results suggest that | 5 |
in this way | 5 |
or mg kg | 5 |
to acknowledge the | 5 |
and adverse events | 5 |
the point of | 5 |
but should be | 5 |
not receive of | 5 |
the study protocol | 5 |
the declaration of | 5 |
in icu patients | 5 |
fda guidance on | 5 |
the remainder of | 5 |
in the present | 5 |
patients and reporting | 5 |
who wish to | 5 |
outside of the | 5 |
reported in the | 5 |
reduction in the | 5 |
will be a | 5 |
directly from the | 5 |
at a dose | 5 |
healthcare workers are | 5 |
are among the | 5 |
is a need | 5 |
to deal with | 5 |
label use of | 5 |
patients in clinical | 5 |
median survival of | 5 |
when patients do | 5 |
data for patients | 5 |
evidence of efficacy | 5 |
our understanding of | 5 |
a tentative solution | 5 |
on trade and | 5 |
of infectious diseases | 5 |
to the medical | 5 |
awake prone positioning | 5 |
respect to the | 5 |
the individual level | 5 |
that we could | 5 |
the pace of | 5 |
and neck cancer | 5 |
stage of the | 5 |
conservation of pangolins | 5 |
of patients to | 5 |
get the ball | 5 |
there will be | 5 |
or nonserious adverse | 5 |
for all three | 5 |
medicines and healthcare | 5 |
may result in | 5 |
of a clinical | 5 |
the gender gap | 5 |
a high incidence | 5 |
to the clinical | 5 |
to the ipad | 5 |
analyses may be | 5 |
to estimate the | 5 |
changing task demands | 5 |
more trials are | 5 |
an overview of | 5 |
be considered for | 5 |
and southeast asia | 5 |
the false discovery | 5 |
of the results | 5 |
all of which | 5 |
patients are not | 5 |
electronic health records | 5 |
of confirmed cases | 5 |
or pneumonic plague | 5 |
of at least | 5 |
trial in phase | 5 |
to south and | 5 |
if the patient | 5 |
clinical trials with | 5 |
results on the | 5 |
reporting data for | 5 |
risk of serious | 5 |
be tested in | 5 |
reported that they | 5 |
a phase i | 5 |
rate in the | 5 |
be recorded in | 5 |
case series and | 5 |
a public health | 5 |
the consent form | 5 |
did not report | 5 |
will be calculated | 5 |
to the drug | 5 |
patients infected with | 5 |
the study period | 5 |
the european union | 5 |
paying research participants | 5 |
the research process | 5 |
and reporting data | 5 |
competing risks analyses | 5 |
grounded theory method | 5 |
responses in the | 5 |
malaria chemoprevention in | 5 |
conditions for each | 5 |
in the number | 5 |
what is the | 5 |
of a harmful | 5 |
majority of the | 5 |
systolic blood pressure | 5 |
of a respirator | 5 |
will be in | 5 |
cell lung cancer | 5 |
the conclusion of | 5 |
the ministry of | 5 |
in a number | 5 |
in other words | 5 |
does not exist | 5 |
to note that | 5 |
stay at home | 5 |
statistical methods and | 5 |
as opposed to | 5 |
median number of | 5 |
health care system | 5 |
in the sense | 5 |
used to treat | 5 |
did not include | 5 |
the testing apparatus | 5 |
for the design | 5 |
in breast cancer | 5 |
small number of | 5 |
streptomycin plus ciprofloxacin | 5 |
malarial drugs for | 5 |
responses in phase | 5 |
is unable to | 5 |
the main limitation | 5 |
to severe psoriasis | 5 |
in the setting | 5 |
of the workshop | 5 |
a change in | 5 |
to consent to | 5 |
be taken to | 5 |
and stored in | 5 |
of their trials | 5 |
of the reviewed | 5 |
a risk of | 5 |
trying out different | 5 |
with a third | 5 |
days alive and | 5 |
ahuja and thatcher | 5 |
for acute respiratory | 5 |
and control groups | 5 |
of systematic errors | 5 |
the inclusion criteria | 5 |
medical research during | 5 |
randomised evaluation of | 5 |
with regulatory agencies | 5 |
and error and | 5 |
practice in the | 5 |
the median number | 5 |
data in clinical | 5 |
in one trial | 5 |
and can be | 5 |
evaluation of covid | 5 |
and the caregiver | 5 |
the state of | 5 |
of the survey | 5 |
of interest for | 5 |
defined based on | 5 |
to achieve this | 5 |
need for mechanical | 5 |
for the management | 5 |
and risk factors | 5 |
after enrollment when | 5 |
composition of the | 5 |
integrity of the | 5 |
was assessed days | 5 |
the time from | 5 |
have also been | 5 |
through trial and | 5 |
and the trial | 5 |
for handling of | 5 |
and mechanical ventilation | 5 |
will be required | 5 |
to address this | 5 |
risk of mortality | 5 |
advantage of the | 5 |
well as a | 5 |
effectiveness and safety | 5 |
is caused by | 5 |
utilization in dementia | 5 |
to changing task | 5 |
acute exacerbations of | 5 |
interpreted with caution | 5 |
in phase was | 5 |
were the most | 5 |
location of the | 5 |
looking at the | 5 |
clinical trial during | 5 |
similar to those | 5 |
the possibility that | 5 |
of serious adverse | 5 |
adverse events will | 5 |
to the sponsor | 5 |
has also been | 5 |
may be helpful | 5 |
to the original | 5 |
resolution of fever | 5 |
and changes in | 5 |
chloroquine in hospitalised | 5 |
effect of standard | 5 |
has never been | 5 |
single target trial | 5 |
transmission in households | 5 |
of good clinical | 5 |
this trial will | 5 |
be possible to | 5 |
a retrospective cohort | 5 |
use of an | 5 |
those of the | 5 |
randomizing patients and | 5 |
trials within cohorts | 5 |
will be included | 5 |
days of remdesivir | 5 |
the gold standard | 5 |
for bubonic plague | 5 |
should be informed | 5 |
other types of | 5 |
for a single | 5 |
a trial and | 5 |
beneficial for covid | 5 |
treatment and care | 5 |
in nursing homes | 5 |
that lead to | 5 |
data can be | 5 |
of all trials | 5 |
medical management arm | 5 |
to the covid | 5 |
of respiratory viruses | 5 |
first presented with | 5 |
the final manuscript | 5 |
randomizing participants compared | 5 |
ministry of health | 5 |
for use in | 5 |
will be offered | 5 |
we used a | 5 |
to be enrolled | 5 |
of clinical studies | 5 |
the pandemic may | 5 |
is to provide | 5 |
to compare the | 5 |
in combination with | 5 |
no conflict of | 5 |
not considered serious | 5 |
to the control | 5 |
events in the | 5 |
and other respiratory | 5 |
across all trials | 5 |
effect of a | 5 |
observational study of | 5 |
as described in | 5 |
conflict of interest | 5 |
of data and | 5 |
healthcare products regulatory | 5 |
the principles of | 5 |
there were no | 5 |
the interpretability of | 5 |
as per the | 5 |
against the target | 5 |
terminology criteria for | 5 |
treatments for coronavirus | 5 |
report on the | 5 |
and the health | 5 |
and implementation of | 5 |
to study treatment | 5 |
azithromycin and chloroquine | 5 |
allowed us to | 5 |
in which children | 5 |
university of medical | 5 |
the research community | 5 |
clinical trials as | 5 |
may be used | 5 |
the change of | 5 |
in case of | 5 |
was applied to | 5 |
aspects of the | 5 |
waiver of consent | 5 |
events with a | 5 |
the first time | 5 |
statistical principles for | 5 |
living systematic reviews | 5 |
full protocol is | 5 |
the treatment policy | 5 |
for a randomized | 5 |
in all the | 5 |
on top of | 5 |
negative correlation between | 5 |
with the general | 5 |
the expense of | 5 |
be beneficial for | 5 |
while on the | 5 |
the era of | 5 |
the size of | 5 |
the pandemic is | 5 |
the first stage | 5 |
mg orally twice | 5 |
the occurrence of | 5 |
trial in the | 5 |
will be given | 5 |
the findings of | 5 |
of pangolins native | 5 |
causal understanding of | 5 |
resource utilization in | 5 |
rest of the | 5 |
benefits and harms | 5 |
in proceedings of | 5 |
of the process | 5 |
the distribution of | 5 |
trial is funded | 5 |
of the available | 5 |
publication of the | 5 |
research involving human | 5 |
personal use scenarios | 5 |
once they are | 5 |
with the ipad | 5 |
recommendations for the | 5 |
preventive treatment with | 5 |
states food and | 5 |
of standard care | 5 |
mashhad university of | 5 |
a need to | 5 |
difference between lopinavir | 5 |
from clinical trials | 5 |
month intervention period | 5 |
informed consent is | 5 |
because they are | 5 |
change of the | 5 |
you get the | 5 |
of the apparatus | 5 |
from phase i | 5 |
side of the | 5 |
the workshop on | 5 |
proceedings of the | 5 |
in the interest | 5 |
are asked to | 5 |
the ability of | 5 |
and clinical trial | 5 |
and approved the | 5 |
the pooled analysis | 5 |
is used to | 5 |
controlled trial date | 5 |
its effects on | 5 |
issues related to | 5 |
trials based on | 5 |
compared to placebo | 5 |
payment for research | 5 |
the week of | 5 |
are described in | 5 |
bubonic or pneumonic | 5 |
are unlikely to | 5 |
we refer to | 5 |
for up to | 5 |
to continue to | 5 |
patient willingness to | 5 |
to test the | 5 |
of treatment and | 5 |
to intensive care | 5 |
which may have | 5 |
to work with | 5 |
clinical trials were | 5 |
of integrative cancer | 5 |
size and the | 5 |
of children in | 5 |
treatment of chronic | 5 |
influenza transmission in | 5 |
k th stage | 5 |
of the two | 5 |
trials were included | 5 |
a sample size | 5 |
that the ipad | 5 |
quintet recruitment intervention | 5 |
will be carried | 5 |
with the trial | 5 |
the intervention group | 5 |
in the pharmaceutical | 5 |
oral cholera vaccine | 5 |
and access to | 5 |
or reject that | 5 |
systematic reviews of | 5 |
in the dexamethasone | 5 |
review of covid | 4 |
compared with standard | 4 |
most commonly used | 4 |
results for the | 4 |
resulted in a | 4 |
statistical analysis plans | 4 |
of critical care | 4 |
event rate in | 4 |
be due to | 4 |
mask use by | 4 |
conducted according to | 4 |
this suggests that | 4 |
of bias trials | 4 |
attending physician who | 4 |
which will be | 4 |
chloroquine with or | 4 |
be affected by | 4 |
of respiratory protection | 4 |
the concept of | 4 |
to patients with | 4 |
to identify and | 4 |
the straw directly | 4 |
for researchers to | 4 |
that the user | 4 |
lopinavir ritonavir plus | 4 |
control and prevention | 4 |
a feasibility study | 4 |
associated with increased | 4 |
forms will be | 4 |
will receive the | 4 |
large proportion of | 4 |
on the time | 4 |
the debate on | 4 |
that in the | 4 |
management of copd | 4 |
measures such as | 4 |
of the overall | 4 |
a good enough | 4 |
interventions to interrupt | 4 |
trial design is | 4 |
treated with a | 4 |
voluntary use of | 4 |
study treatment discontinuation | 4 |
pwd and the | 4 |
the hpa axis | 4 |
behaviour and cognition | 4 |
at the conclusion | 4 |
olds made efficient | 4 |
with mild to | 4 |
pnif and npr | 4 |
the key elements | 4 |
compliance with the | 4 |
and routinely collected | 4 |
be considered when | 4 |
a majority of | 4 |
in the trials | 4 |
science and technology | 4 |
study designs and | 4 |
and hand hygiene | 4 |
and recommendations for | 4 |
public health practice | 4 |
and on day | 4 |
data sharing and | 4 |
geriatric clinical trials | 4 |
using the following | 4 |
systematic review with | 4 |
for the success | 4 |
cancer patients in | 4 |
results can be | 4 |
and prevention of | 4 |
wei bushen yiqi | 4 |
also been used | 4 |
than the younger | 4 |
accessible from the | 4 |
clinical trials related | 4 |
randomly assigned to | 4 |
window of opportunity | 4 |
of the key | 4 |
azithromycin as a | 4 |
the first case | 4 |
purpose of this | 4 |
their time and | 4 |
the tablet with | 4 |
malarial drug safety | 4 |
two or more | 4 |
mg kg every | 4 |
removing the straw | 4 |
straw directly below | 4 |
expediting dissemination of | 4 |
of randomized trials | 4 |
by healthcare workers | 4 |
offers of payment | 4 |
most efficient solution | 4 |
in the who | 4 |
that were not | 4 |
by the norwegian | 4 |
receive placebo plus | 4 |
discharge from the | 4 |
or without a | 4 |
as adjunctive therapy | 4 |
department of health | 4 |
the patients will | 4 |
the anatomy of | 4 |
of the first | 4 |
be considered to | 4 |
or a fourfold | 4 |
relative to the | 4 |
the use and | 4 |
ageing and health | 4 |
in antibody titre | 4 |
of included trials | 4 |
efficiency in phase | 4 |
the significance of | 4 |
quadrivalent rhesus rotavirus | 4 |
streptomycin and ciprofloxacin | 4 |
and after the | 4 |
the medical community | 4 |
generalizability of the | 4 |
cannabis use disorder | 4 |
switch to oral | 4 |
were unable to | 4 |
different categories of | 4 |
disruptions due to | 4 |
the largest trial | 4 |
improve health and | 4 |
authors contributed to | 4 |
be administered by | 4 |
of this vaccine | 4 |
due to contact | 4 |
should be used | 4 |
realistic intervention effects | 4 |
for research in | 4 |
of this trial | 4 |
we have not | 4 |
the sponsor and | 4 |
the probability of | 4 |
of baseline severity | 4 |
genv proposes to | 4 |
infection in a | 4 |
coronavirus disease in | 4 |
was used for | 4 |
consultation with a | 4 |
reduce the need | 4 |
estimates of vaccine | 4 |
the criteria for | 4 |
different action sequences | 4 |
with a specific | 4 |
as outlined in | 4 |
there have been | 4 |
low to very | 4 |
is to define | 4 |
will be considered | 4 |
be required for | 4 |
studies may be | 4 |
over time and | 4 |
a timely fashion | 4 |
conduction of clinical | 4 |
length of stay | 4 |
randomized control trial | 4 |
a small number | 4 |
trial efficacy and | 4 |
our aim was | 4 |
introduction of new | 4 |
of dexamethasone on | 4 |
reporting of clinical | 4 |
assess the effect | 4 |
should be evaluated | 4 |
interventions for covid | 4 |
mind at home | 4 |
when first presented | 4 |
medical research involving | 4 |
and timing of | 4 |
relies on the | 4 |
tests will be | 4 |
effects of all | 4 |
body of evidence | 4 |
evaluate the clinical | 4 |
in the elderly | 4 |
trials and their | 4 |
number of registered | 4 |
occur due to | 4 |
drugs in pregnancy | 4 |
authors declare no | 4 |
this is especially | 4 |
to limit the | 4 |
sequence will be | 4 |
action sequences used | 4 |
high flow therapy | 4 |
the treatment group | 4 |
the interim analysis | 4 |
based upon the | 4 |
the trials that | 4 |
relevant to the | 4 |
a coefficient of | 4 |
work from home | 4 |
the current situation | 4 |
to carry out | 4 |
cause mortality with | 4 |
effects of remdesivir | 4 |
in the statistical | 4 |
the quality and | 4 |
contrast to phase | 4 |
coronavirus named severe | 4 |
not have a | 4 |
to contact with | 4 |
leading to a | 4 |
across age groups | 4 |
international classification of | 4 |
eligible patients will | 4 |
the writing group | 4 |
terms of timing | 4 |
is imperative that | 4 |
to the treatment | 4 |
which is the | 4 |
specified in the | 4 |
the final cumulative | 4 |
deemed clinically appropriate | 4 |
remainder of the | 4 |
of the network | 4 |
with the it | 4 |
study and the | 4 |
the study of | 4 |
attention to the | 4 |
be viewed as | 4 |
of treatment effects | 4 |
we consider that | 4 |
description of the | 4 |
septoplasty versus medical | 4 |
would have agreed | 4 |
in task configuration | 4 |
trials and the | 4 |
find the food | 4 |
interpretation of data | 4 |
will be published | 4 |
funded by the | 4 |
for the scientific | 4 |
patient information sheet | 4 |
of the lack | 4 |
a need for | 4 |
supplementary video s | 4 |
the inclusion and | 4 |
should be the | 4 |
in need of | 4 |
determined by the | 4 |
a focus on | 4 |
research may be | 4 |
the eligibility criteria | 4 |
of the sponsor | 4 |
of the questionnaire | 4 |
effect of covid | 4 |
the quintet recruitment | 4 |
the study drug | 4 |
and azithromycin as | 4 |
to be recruited | 4 |
is supported by | 4 |
the conditions for | 4 |
along with the | 4 |
of access to | 4 |
recorded in the | 4 |
of care for | 4 |
able to swallow | 4 |
of its use | 4 |
the nose and | 4 |
all the data | 4 |
frequency oscillatory ventilation | 4 |
charge of the | 4 |
use of rescue | 4 |
for data management | 4 |
creative commons attribution | 4 |
the medical research | 4 |
evaluate the impact | 4 |
clinical development of | 4 |
to consider the | 4 |
our empirical material | 4 |
patients in each | 4 |
other forms of | 4 |
novel coronavirus disease | 4 |
need for a | 4 |
might need to | 4 |
familiar formatting has | 4 |
outcomes in the | 4 |
to complete their | 4 |
safety monitoring boards | 4 |
such as covid | 4 |
order to overcome | 4 |
and secondary outcomes | 4 |
can be applied | 4 |
see supplementary video | 4 |
to do something | 4 |
for six trials | 4 |
phase iii rcts | 4 |
and there are | 4 |
in some cases | 4 |
were reported in | 4 |
framework for the | 4 |
a pathway for | 4 |
transferred to the | 4 |
about how to | 4 |
trial is a | 4 |
in detail in | 4 |
involved in clinical | 4 |